Summary Slide.png (59.91 kB)

Cost-Effectiveness Analysis of Atezolizumab plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non–Small Cell Lung Cancer

figure

posted on 2020-03-18, 10:16 authored by Dong Ding, Huabin Hu, Mengting Liao, Yin Shi, Longjiang She, Linli Yao, Youwen Zhu, Shan Zeng, Jin Huang

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s12325-020-01292-3

Usage metrics

Read the peer-reviewed publication

Cost-Effectiveness Analysis of Atezolizumab plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non–Small Cell Lung Cancer

Advances in Therapy

Keywords

Atezolizumab Cost-effectiveness Non-small cell lung cancer Oncology

Licence

CC BY-NC 4.0

Cost-Effectiveness Analysis of Atezolizumab plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non–Small Cell Lung Cancer

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports